$AEON

AEON Biopharma, Inc. has a lock-up agreement ending on 12-OCT-2026, with a 90-day lock-up period starting 14-JUL-2026. The company, its executives, and certain stockholders are subject to the lock-up, with exceptions for warrant exercises and NYSE American listing compliance. AEON is a clinical-stage biopharmaceutical company focused on developing ABP-450 for medical conditions like migraine and PTSD.

Analysts updated price targets for several companies. Citigroup raised HPE's target to $92. Goldman Sachs increased PSX's target to $274. Raymond James cut LQDA's target to $53. Mizuho boosted MU's target to $1,400. Lake Street raised AEON's target to $2. Morgan Stanley lowered AAPL's target to $355. JP Morgan reduced ZION's target to $65. Evercore ISI cut WFC's target to $90. UBS increased DT's target to $74. Guggenheim raised NFLX's target to $80.

Aeon Biopharma's shares rose 19% after the FDA agreed with its study design for ABP-450, a Botox biosimilar. The company plans to submit an investigational new drug application in Q4, with a market cap of $15 million (NYSE: AEON).

AEON Biopharma received FDA feedback on its biosimilar ABP-450, clarifying the development path. The FDA agreed to consider previous studies as supportive evidence and recommended a pharmacodynamic study. AEON plans to submit an IND for this study in Q4 2026 and aims to streamline development, potentially avoiding a full clinical efficacy study. The company expects to return to the FDA in 2027 with its evidence package.

Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.

Aeon Biopharma reported positive results from a stress test comparing its ABP-450 treatment to Botox, showing similar degradation under thermal and oxidative stress. The company plans a multi-lot comparability study. Shares of Aeon were up 1% to 23 cents, with a market cap of $11.8 million.

On Friday, notable insider trading activity was reported for several US-listed companies. Global Water Resources (GWRS) directors bought shares, with Jonathan L. Levine acquiring 651,618 shares at $8.85 each. AEON Biopharma (AEON) director Timothy P. Lynch purchased 1.15M shares at $0.2117 each. Cloudflare (NET) president Michelle Zatlyn sold $28.3M worth of shares. Illumina (ILMN) director Keith A. Meister sold $145.56M in shares. InvestingPro analysis provided valuation insights for these comp

AEON Biopharma (AEON) filed a Schedule 13G reporting that Timothy P. Lynch owns 6,500,000 shares (13% of Class A stock). Lynch has sole voting and dispositive power over these shares. The filing also notes additional warrants for 7,000,000 shares are blocked due to a 4.99% ownership cap.

LYNCH TIMOTHY P purchased 1,150,000 shares of AEON Biopharma, Inc. (AEON) at $0.21 ($0.24M total) on 2026-08-19.

AEON Biopharma reported expanded data supporting molecular similarity of ABP-450 to BOTOX, achieving 98% sequence coverage with 100% amino acid identity. Preliminary analysis confirmed critical disulfide bond structure. FDA feedback expected to guide next development phase. ABP-450 aims for full-label U.S. market entry as a biosimilar to BOTOX.